Cannabis and Anxiety: A Critical Review
Alexander Beletsky, Cherry Liu, Bryson Lochte, Nebiyou K. Samuel, Igor Grant
Medical Cannabis and Cannabinoids February 23, 2024 DOI: 10.1159/000534855 (opens in new tab)
Study at a glance
AI-extracted from the abstractAbstract
Abstract
Introduction: Cannabis has been reported to have both anxiogenic and anxiolytic effects. Habitual cannabis use has been associated with anxiety disorders (AD). The causal pathways and mechanisms underlying the association between cannabis use (CU)/cannabis use disorder (CUD) and anxiety remain unclear. We examined the literature via a systematic review to investigate the link between cannabis and anxiety. The hypotheses studied include causality, the common factor theory, and the self-medication hypothesis.
Methods: Critical systematic review of published literature examining the relationship of CU/CUD to AD or state-anxiety, including case reports, literature reviews, observational studies, and preclinical and clinical studies. A systematic MEDline search was conducted of terms including: [anxiety], [anxiogenic], [anxiolytic], [PTSD], [OCD], [GAD], [cannabis], [marijuana], [tetrahydrocannabinol], [THC].
Results: While several case-control and cohort studies have reported no correlation between CU/CUD and AD or state anxiety (N = 5), other cross-sectional, and longitudinal studies report significant relationships (N = 20). Meta-analysis supports anxiety correlating with CU (N = 15 studies, OR = 1.24, 95% CI: 1.06–1.45, p = 0.006) or CUD (N = 13 studies, OR = 1.68, 95% CI: 1.23–2.31, p = 0.001). PATH analysis identifies the self-medication hypothesis (N = 8) as the model that best explains the association between CU/CUD and AD or state-anxiety. Despite the support of multiple large cohort studies, causal interpretations (N = 17) are less plausible, while the common factor theory (N = 5), stress-misattribution hypothesis, and reciprocal feedback theory lack substantial evidential support.
Conclusion: The association between cannabis and anxiety is best explained by anxiety predisposing individuals toward CU as a method of self-medication. A causal relationship in which CU causes AD incidence is less likely despite multiple longitudinal studies suggesting so.
Comparable studies
Other systematic reviews and meta-analyses on cannabis for anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review | 2020 | Systematic review | |
| Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties | 2020 | Systematic review | |
| What are the psychological effects of using synthetic cannabinoids? A systematic review Synthetic cannabinoid users, natural cannabis users, and non-users from 17 studies | 2019 | Systematic review | |
| “Noids” in a nutshell: everything you (don’t) want to know about synthetic cannabimimetics | 2014 | Systematic review and descriptive analysis | |
| Subjective, behavioral and neurobiological effects of cannabis and cannabinoids in social anxiety. Patients with social anxiety disorder or healthy volunteers performing tasks that... | 2024 | Systematic review |
Citations in the library
Cited by 4
- Beyond the Diagnostic Binary: A Translational Use of the Research Domain Criteria to Improve the Measurement of Anxiety in the Context of Cannabis Use Healthcare August 1, 2026
- Cannabis and Mental Health: A Review. JAMA Internal Medicine May 1, 2026
- The Pharmacology of Delta-9-Tetrahydrocannabinol (THC) The Science of Marijuana 2019
- Peripheral and Central Effects of THC The Science of Marijuana 2019
Cites 4
- The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial PLoS One March 17, 2021
- Effects of Endocannabinoid System Modulation on Cognitive and Emotional Behavior Frontiers in Behavioral Neuroscience July 22, 2011
- The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology August 2004
- Role of endocannabinoid system in mental diseases. Neurotoxicity Research 2004